Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 6, 2002

View Archived Issues

Potential use of efalizumab in the treatment of T-cell-mediated diseases

The ETA receptor antagonist BQ-123 prevents endothelial dysfunction induced by mental stress

Adjuvant QS-21 enhances immunogenicity of malaria peptide vaccine

Transkaryotic Therapies announces second quarter highlights

Alizyme offers six-month progress report

Neurodex enters phase II trial in diabetic neuropathic pain

Biopure submits Hemopure BLA

Xyotax enters phase II trial in breast cancer

Initiation of phase II/III trial of CEP-1347 in early-stage Parkinson's disease

MT-400 development program agreed with FDA and MCA

MTC-DOX designated orphan drug in E.U.

Novel glucokinase activators described in Roche patent

Merck Frosst presents caspase-3 inhibitors with potential in ischemic disorders

Novel topoisomerase I inhibitors in Advanced Life Sciences pipeline

Akzo Nobel researchers identify new androgenic/progestagenic compounds

Bayer claims novel beta3-adrenoceptor agonists for diabetes, obesity, etc.

New quinolones and quinolizinones in early development at P&G

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...